Dr Christopher Rapuano reviews surprising and questionable corneal graft survival rates between two surgical techniques. Medscape Ophthalmology
Uncategorized
Publication Exclusive: Troubleshooting the initiation of cyclosporine for dry eye
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.Dry eye disease is one of the most frequently seen problems in the eye care professional’s office. Cyclosporine drops have become the mainstay of treatment of this condition. Some physicians have noted difficulty with the initiation of cyclosporine due to the delay in onset and the subjective irritation some patients note upon instillation. This month, Jonathan D. Solomon, MD, and Cynthia A. Matossian, MD, FACS, discuss their strategies to initiate cyclosporine with their patients. We hope you enjoy this discussion.
Scientists uncover five genetic markers for glaucoma
Scientists have discovered new genetic areas linked to an increased risk of glaucoma – the leading cause of irreversible blindness worldwide.
Uncategorized
Aura Biosciences to Present at the 15th Annual Needham Healthcare Conference
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences announced today that Elisabet de los Pinos, founder and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference in New York, N.Y.
Mount Sinai Health System recognized as ‘Leaders in LGBT Healthcare Equality’ by HRC Foundation
Six campuses of the Mount Sinai Health System – The Mount Sinai Hospital, Mount Sinai Beth Israel, Mount Sinai St. Luke’s, Mount Sinai West (formerly known as Mount Sinai Roosevelt), Mount Sinai Queens, and New York Eye and Ear Infirmary of Mount Sinai…
Acucela Licenses Gene Therapy from The University of Manchester for Retinal Degenerative Disease
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, and The University of Manchester, UK (“UoM”), announced today an exclusive license agreement whereby Acucela will develop and commercialize UoM’s human rhodopsin based optogenetic gene therapy1 for the treatment of retinal degenerative disease, includi